3368-21-6

Basic information

• Product Name: 4-ISOPROPYLCINNAMIC ACID
• Synonyms: 4-Isopropylcinnamic acid, predominantly trans, 98+%;3-[4-(1-Methylethyl)phenyl]propenoic acid;2-propenoic acid, 3-[4-(1-methylethyl)phenyl]-, (2E)-;4-Isopropylcinnamic Acid, Predominantly Trans;3-[4-(1-Methylethyl)phenyl]-2-propenoic acid;NSC 216;trans-4-Isopropylcinnamic acid;OTAVA-BB BB0109160007
• CAS NO: 3368-21-6
• Molecular Formula: C₁₂H₁₄O₂
• Molecular Weight: 190.24
• EINECS: 222-138-2
• Product Categories: Aromatic Cinnamic Acids, Esters and Derivatives
• Mol File: 3368-21-6.mol
• Article Data: 18

Chemical Properties

• Melting Point: 157-159°C
• Boiling Point: 317℃
• Flash Point: 222℃
• Appearance: white crystalline powder.
• Density: 1.086
• Vapor Pressure: 0.000167mmHg at 25°C
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 4.54±0.10(Predicted)
• Stability: Hygroscopic
• BRN: 2046679
• CAS DataBase Reference: 4-ISOPROPYLCINNAMIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ISOPROPYLCINNAMIC ACID(3368-21-6)
• EPA Substance Registry System: 4-ISOPROPYLCINNAMIC ACID(3368-21-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 3368-21-6(Hazardous Substances Data)

Usage

Chemical Properties

white crystalline powder

InChI:InChI=1/C12H14O2/c1-9(2)11-6-3-10(4-7-11)5-8-12(13)14/h3-9H,1-2H3,(H,13,14)/p-1/b8-5+

Upstream product

• 74389-78-9 (E)-4-(4-isopropylphenyl)but-3-en-2-one 
• 122-03-2 (4-isopropylbenzaldehyde) 
• 128408-02-6 ethyl (E)-3-(4-isopropylphenyl)-2-propenoate 
• 141-82-2 malonic acid 
• 110-89-4 piperidine 
• 32580-69-1 4-isopropyl-cinnamic acid ethyl ester 
• 59577-61-6 (4-isopropyl-benzylidene)-malonic acid 
• 7664-93-9 sulfuric acid 
• 872821-12-0 3-hydroxy-3-(4-isopropyl-phenyl)-propionic acid 
• 108-24-7 acetic anhydride 
• 110-86-1 pyridine 

Downstream Products

• 181954-87-0 3-(4-isopropyl-phenyl)-propionyl chloride 
• 42348-89-0 6-isopropylindan-1-one 
• 934192-41-3 dithiocarbonic acid S-[3-(acetyl-allyl-amino)-1-(4-isopropyl-phenyl)-3-oxo-propyl] ester O-ethyl ester 
• 69358-86-7 (E)-methyl 3-(p-isopropylphenyl)prop-2-enoate 
• 642093-52-5 (E)-1-bromo-2-(4-isopropylphenyl)ethene 
• 58420-21-6 3-(p-isopropylphenyl)propionic acid 
• 244759-45-3 (E)-3-(4-isopropylphenyl)acryloyl chloride 
• 846552-80-5 4-isopropylcinnamoyl chloride 
• 619-89-6 p-nitrocinnamic acid 
• 77261-90-6 2-(4-Isopropyl-phenyl)-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one 

Relevant articles and documents

Photo-Promoted Decarboxylative Alkylation of α, β-Unsaturated Carboxylic Acids with ICH2CN for the Synthesis of β, γ-Unsaturated Nitriles

An efficient, catalyst/photocatalyst-free, and cost-effective methodology for the decarboxylative alkylation of α,β-unsaturated carboxylic acids to synthesize β,γ-unsaturated nitriles has been developed. The reaction proceeded in an environmentally benign atmosphere of blue light-emitting diode irradiation with K2CO3 and water at room temperature. The methodology worked for a wide range of substrates (22 examples) with up to 83% yield. The protocol is also compatible for gram-scale synthesis.

Dual-targeting Rutaecarpine-NO donor hybrids as novel anti-hypertensive agents by promoting release of CGRP

CGRP, known as the most potent vasodilator substance, plays an important role in hypertension initiation and development. TRPV1 and TRPA1 are critical in promoting the synthesis and release of CGRP, thereby regulating the cardiovascular tone. Rutaecarpine exhibits potent vasodilator and hypertensive effects by stimulating CGRP synthesis and release via activation of TRPV1. And NO has been shown to react with H2S in vivo to form HNO, thereby activating HNO-TRPA1-CGRP pathway. Inspired by combination therapy, 11 rutaecarpine-furoxan hybrids were designed, synthesized and evaluated. The results demonstrated that most hybrids exerted comparable or improved vasodilator activities. Among which, 13a is the most potent both ex vivo (EC50 = 13.1 nM) and in vivo. Mechanistic studies revealed that the vasodilator and anti-hypertensive effects of the hybrids might involve the promotion of CGRP release via dual activation of TRPV1 and TRPA1. This work suggests that dual-targeted hybrids might be an effective and promising approach to discover and develop novel anti-hypertensive drugs.

Chiral phosphoric acid catalyzed enantioselective annulation of acyclic enecarbamates to: In situ -generated ortho -quinone methides

The first organocatalytic asymmetric reaction of acyclic enecarbamates with o-quinone methides is disclosed. BINOL-based phosphoric acid catalysts were found to be suitable for the annulation reaction. With 10 mol% of the TRIP catalyst, high yields as well as excellent diastereo- and enantioselectivities are achieved for a variety of 2,3,4-trisubstituted chroman products.